netakimab vs vunakizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriatic Arthritis

Shared mechanism: IL-17 · full Psoriatic Arthritis pipeline

netakimab

Marketed by Biocad

Phase 3 in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT03598751 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 194 patients. The proportion of patients achieving a validated joint-response measure (ACR20) was overwhelmingly higher with netakimab than placebo, a gap large enough to leave no real doubt about the direction of the effect even though a formal statistical test was not reported in the source used.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

ACR 20 (week 24): ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo. (met)

Result source: NCT03598751

vunakizumab

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Psoriatic Arthritismonoclonal antibody
Partial signal

NCT05055934 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 112 participants, using the clinical ACR20 improvement measure as its primary endpoint. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Proportion of subjects achieving ACR 20 improvement at week 12: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively (met)

Result source: NCT05055934

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointnetakimabvunakizumab
ACR2082% vs 9%a+73 vs placebowk 24NCT03598751—Trial running · NCT06640257
ACR50—Not posted · NCT03598751—Trial running · NCT06640257
PASI 75—Not posted · NCT03598751—Trial running · NCT06640257
Minimal disease activity—Not posted · NCT03598751—Trial running · NCT06640257
HAQ-DI, change—Not posted · NCT03598751—Trial running · NCT06640257

ACR20

netakimab
82% vs 9%a+73 vs placebowk 24NCT03598751
vunakizumab
—Trial running · NCT06640257

ACR50

netakimab
—Not posted · NCT03598751
vunakizumab
—Trial running · NCT06640257

PASI 75

netakimab
—Not posted · NCT03598751
vunakizumab
—Trial running · NCT06640257

Minimal disease activity

netakimab
—Not posted · NCT03598751
vunakizumab
—Trial running · NCT06640257

HAQ-DI, change

netakimab
—Not posted · NCT03598751
vunakizumab
—Trial running · NCT06640257
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

vunakizumab
ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively NCT05055934 · Phase 2 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

netakimab

ACR20 82% vs 9% placebo @ 24wk
responder rate · % of participants
NCT03598751 · Phase 3 · sponsor-reported, not registry data

Psoriasis

Shared mechanism: IL-17 · full Psoriasis pipeline

netakimab

Marketed by Biocad

Phase 3 in Psoriasismonoclonal antibody
Reliable signal

NCT03390101 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 213 participants and a clinical psoriasis endpoint (PASI 75) assessed at week 12. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.

Reported efficacy

• The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%) (met)

Result source: NCT03390101

vunakizumab

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Psoriasismonoclonal antibody
Reliable signal

NCT04839016 · Phase 3 · status unknown

This randomized, double-blind, placebo-controlled Phase 3 trial randomized 690 patients with moderate-to-severe plaque psoriasis 2:1 to vunakizumab 240 mg or placebo. The co-primary endpoints were PASI 90 and sPGA 0/1 at week 12. PASI 90 was reached by 76.8% of patients on vunakizumab and 0.9% on placebo, and sPGA 0/1 by 71.8% and 0.4% (both two-sided P < .0001), so both co-primary endpoints were met. The registry record still shows its 2021 estimated enrollment of 660 and has no posted results; the figures come from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025).

Caveat: this result is taken from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025, PMID 39332633); the ClinicalTrials.gov record (status unknown) has no posted results.

Next expected readout: March 2027 · NCT06779097 (registry estimate)

Reported efficacy

Percentage of subjects who achieve at least 90% improvement in PASI score (PASI 90) at Week 12; sPGA of 0 or 1 response at Week 12: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). (met)

Result source: NCT04839016

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointnetakimabvunakizumab
PASI 7577.6% vs 0%+77.6 vs placeboQ2W · wk 12 · n 85NCT03390101
4 other results
  • 83.3% vs 0% Q4W · wk 12 · n 84 · Phase 3 · primary NCT03390101
  • 92.9% vs 23.1% 120 mg · wk 12 · n 28 · Phase 2 · primary NCT02762994
  • 83.3% vs 23.1% 80 mg · wk 12 · n 30 · Phase 2 · primary NCT02762994
  • 80% vs 23.1% 40 mg · wk 12 · n 30 · Phase 2 · primary NCT02762994
—Trial running · NCT06833307
PASI 90—Not posted · NCT07008547—Trial running · NCT06833307
PASI 100—Not posted · NCT07008547—Trial running · NCT06833307
sPGA 0/1—Not posted · NCT07008547—Trial running · NCT06833307
DLQI, change—Not posted · NCT07008547—Trial running · NCT06833307

PASI 75

netakimab
77.6% vs 0%+77.6 vs placeboQ2W · wk 12 · n 85NCT03390101
4 other results
  • 83.3% vs 0% Q4W · wk 12 · n 84 · Phase 3 · primary NCT03390101
  • 92.9% vs 23.1% 120 mg · wk 12 · n 28 · Phase 2 · primary NCT02762994
  • 83.3% vs 23.1% 80 mg · wk 12 · n 30 · Phase 2 · primary NCT02762994
  • 80% vs 23.1% 40 mg · wk 12 · n 30 · Phase 2 · primary NCT02762994
vunakizumab
—Trial running · NCT06833307

PASI 90

netakimab
—Not posted · NCT07008547
vunakizumab
—Trial running · NCT06833307

PASI 100

netakimab
—Not posted · NCT07008547
vunakizumab
—Trial running · NCT06833307

sPGA 0/1

netakimab
—Not posted · NCT07008547
vunakizumab
—Trial running · NCT06833307

DLQI, change

netakimab
—Not posted · NCT07008547
vunakizumab
—Trial running · NCT06833307
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

vunakizumab
Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). NCT04839016 · Phase 3 · design grade: strong · publication or press release
PASI 75 at week 12: 56.8% (40 mg), 65.8% (80 mg), 81.6% (160 mg), and 86.5% (240 mg) vs 5.4% placebo; P < .001 for all NCT03463187 · Phase 1/2 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. netakimab: 3 of 4 rows · vunakizumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricnetakimab
Dropout rate
0%Q2Wa
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3
show 4 more results
2.4%Q4W
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3
6.7%120 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
3.2%80 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
3.2%40 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—Q2Wa
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3
show 4 more results
—Q4W
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3
—120 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
—80 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
Serious AEs
0%Q2Wa
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3
show 4 more results
1.2%Q4W
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3
0%120 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
0%80 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
Q2Wa
hyperbilirubinemia 4.7% (placebo 2.3%)
neutropenia 3.5% (placebo 0%)
alanine aminotransferase increased 1.2% (placebo 0%)
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3
show 4 more results
Q4W
hyperglycaemia 3.6% (placebo 0%)
hyperbilirubinemia 2.4% (placebo 2.3%)
leukopenia 2.4% (placebo 0%)
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3
120 mg
arterial bp increased 10.7% (placebo 0%)
arvi 3.6% (placebo 3.6%)
flu-like symptoms 3.6% (placebo 0%)
NCT02762994 · Phase 2 · registry result, not featured evidence
80 mg
ggt increased 10% (placebo 7.1%)
arterial bp increased 6.7% (placebo 0%)
neutropenia 6.7% (placebo 3.6%)
NCT02762994 · Phase 2 · registry result, not featured evidence
40 mg
neutropenia 12.9% (placebo 3.6%)
arvi 9.7% (placebo 3.6%)
conjuctivitis 3.2% (placebo 0%)
NCT02762994 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

netakimab

PASI 75 92.9% (n=28) vs 23.1% (n=26) placebo @ 12wk120 mg
responder rate · % of participants
NCT02762994 · Phase 2 · registry result, not featured evidence · converted to % from 26 Participants as posted
show 4 more results
83.3% (n=30) vs 23.1% (n=26) placebo @ 12wk*80 mg
NCT02762994 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
80% (n=30) vs 23.1% (n=26) placebo @ 12wk*40 mg
NCT02762994 · Phase 2 · registry result, not featured evidence · converted to % from 24 Participants as posted
77.6% (n=85) vs 0% (n=44) placebo @ 12wk*Q2W
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 66 Participants as posted
83.3% (n=84) vs 0% (n=44) placebo @ 12wk*Q4W
NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 70 Participants as posted
NAPSI 66.37% (n=19) vs 7.828% (n=12) placebo @ 12wk120 mg
percent change · % of baseline
NCT02762994 · Phase 2 · registry result, not featured evidence
show 2 more results
47.095% (n=18) vs 7.828% (n=12) placebo @ 12wk80 mg
NCT02762994 · Phase 2 · registry result, not featured evidence
25.204% (n=17) vs 7.828% (n=12) placebo @ 12wk40 mg
NCT02762994 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: netakimab's landscape · vunakizumab's landscape